Objective We evaluated the bladder cancer risk associated with coffee consumption in a case-control study in Spain and examined the gene-environment interactions for genetic variants of caffeine-metabolizing enzymes. Methods The analyses included 1,136 incident cases with urothelial carcinoma of the urinary bladder and 1,138 controls. Odds ratios (OR) and 95% confidence intervals (CI) were adjusted for area, age, gender, amount of cigarette smoking, and years since quitting among former smokers.
Introduction
Coffee is a complex mixture of chemicals. The carcinogenic potential of coffee has been examined in animal studies with inconsistent results [1] . In humans, epidemiological studies suggest that coffee is possibly carcinogenic to the urinary bladder [1] , although evidence remains controversial [2] . A number of studies have reported a positive association [3] [4] [5] [6] [7] that was not replicated in other studies [8] [9] [10] [11] . The body of evidence excludes a strong effect, and causality is questioned given the moderate association, a lack of a clear dose-response, and the potential residual confounding by smoking [12] [13] [14] .
Apart from a recent evaluation [15] , the interplay between coffee consumption and genetic susceptibility on bladder cancer risk has not been examined. In humans, caffeine is mainly metabolized by cytochrome P450 (CYP) 1A2 enzyme in the liver. Additional CYPs isoforms (e.g., CYP1A1, 2E1, 3A4), N-acetyltransferase 2 (NAT2) and xanthine oxidase (XO) also appear to be involved in the formation of certain secondary metabolites [16] [17] [18] . However, genetic variants of most of those genes have not been examined in relation to the bladder cancer risk by coffee consumption.
We evaluated the association between coffee consumption and bladder cancer risk in a case-control study conducted in Spain and examined the gene-environment interactions for variants of genes coding for caffeinemetabolizing enzymes.
Material and methods

Study design and population
We conducted a multicenter hospital-based case-control study of bladder cancer between June 1998 and June 2001 in Spain. Study subjects were recruited in 18 participating hospitals from five areas: Barcelona, Vallès/Bages (including two cities: Sabadell and Manresa), Alicante, Tenerife, and Asturias. Cases were identified through the hospital urological services at diagnosis and were patients with newly diagnosed histologically confirmed primary bladder cancer, aged between 20 and 80 years and living in the catchment area of the participating hospitals. In addition to registries from urological services, complete case ascertainment was secured by regular evaluations of hospital discharge records, pathology records, and local cancer registries. Controls were patients with diagnoses unrelated to the bladder cancer risk factors under study, particularly tobacco use. They were individually matched to cases by gender, age group (5-year strata), and residence area. Controls were admitted to hospitals for hernias (37%), other abdominal surgery (11%), fractures (23%), other orthopedic problems (7%), hydrocele (12%), circulatory disorders (4%), dermatological disorders (2%), ophthalmologic disorders (1%), and other diseases (3%). The study was approved by the ethics committees of the participating centers, and subjects were enrolled after written informed consent.
Personal information and response rates
Trained interviewers administered a comprehensive computer-assisted personal interview (CAPI) to the participants during their hospital stay. Collected information included socio-demographic characteristics, smoking habits, coffee consumption, occupational, residential and medical histories, and familial history of cancer. A food frequency questionnaire was self-administered. We identified 1,457 eligible cases and 1,465 eligible controls. Among these, 84% of cases (n = 1,219) and 88% of controls (n = 1,271) responded to the questionnaire. Biological samples for DNA analyses were obtained from 97% of cases and 91% of controls. Of these, 88.5% were based on blood samples (94% cases, 83% controls), and the rest were from buccal cell samples.
Coffee data
We ascertained whether participants had ever consumed coffee, age when started and quit coffee consumption, and the average amount consumed per day during adult life. The actual questions were ''Did you ever drink at least one cup of coffee per week for a year or longer?''; ''How old were you when you first had at least one cup of coffee per week?''; ''How old were you when you last drank coffee?''; and ''Thinking about all the years that you drank coffee over most of your adult life, which could be different from what you do now, how many cups of coffee did you usually drink per day?''. These questions were repeated separately for decaffeinated and regular coffee.
Genotyping
Single nucleotide polymorphisms (SNPs) were analyzed in DNA extracted from leukocytes (1, 107 [19, 20] . The description and methods for each assay can be found at http://snp500cancer.nci.nih.gov. The four genes included in this analysis were selected from the literature based on their effect on caffeine metabolism (CYP1A2, CYP1A1, CYP2E1 and NAT2). SNP selection favored nonsynonymous SNPs, those previously evaluated in relation to cancer risk or those with evidence of functional significance. All studied SNPs were under Hardy-Weinberg equilibrium in the control population and with minor allele frequency (MAF) [0.05. Pairwise linkage disequilibrium (LD) between SNPs was estimated based on D 0 and r 2 values using R.
Statistical analysis
Ever coffee consumption was defined as having ever drunk at least one cup of coffee per week for 1 year or longer. Coffee consumers were grouped in categories according to cups of coffee consumed per day: 1, 2, 3, and 4 or more. We calculated odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression adjusting for area, age, gender, amount of smoking (3 categories: never, 0-19 and 20? cigarettes/day), and years since quitting among former smokers (continuous). Former and current smokers smoked 100 cigarettes or more in their lifetime and at least 1 cigarette/day during 6 months or longer. Former smokers who quit less than 1 year before interview were considered current smokers. Odds ratios were calculated separately for never, former, and current smokers. The potential interactions of each individual SNP and high versus low coffee intake (C4 vs.\4 cups/day) were evaluated by introducing interaction terms in logistic regression models. Haplotype frequencies for genes with more than one SNP and their interaction with coffee were estimated using SNPstats (http://bioinfo.iconcologia.net/index.php?module=Snpstats).
To adjust for multiple testing, the false discovery rate (FDR) test was applied [21] . Analyses of coffee main effects were limited to 1,136 cases with urothelial carcinoma of the urinary bladder and 1,138 controls with available information on amount of coffee consumption and smoking status. Genetic analyses were based in a subset of 1,126 cases and 1,117 controls with available DNA data.
Results
Characteristics of the study population are shown in Table 1 . Eighty-seven percent of study subjects had ever consumed coffee (89% of cases, 85% of controls). By gender, 89% of men versus 79% of women had ever consumed coffee. Coffee consumers drank on average 2.4 cups/day. Study subjects had difficulties at disentangling regular from decaffeinated coffee consumption when asked separately. Data on amount of regular and decaffeinated coffee consumption separately were missing in 15% and 28% of study subjects, respectively. Available data showed that ever consumption of decaffeinated coffee (72% of study population) was lower than regular coffee consumption (78%). Average consumption of regular and decaffeinated coffee was 2.5 cups/day (standard deviation, SD 3.2) and 1.6 cups/day (SD 1.1) among ever consumers, respectively. Table 2 shows the relationship between coffee consumption and smoking status in our study subjects. Coffee consumption was correlated with smoking habits. Number of daily cups of coffee increased in former and current smokers, smokers of 20 cigarettes/day or more, former smokers quitting recently (\5 years), and blond tobacco smokers. However, coffee consumption was independent of duration of smoking.
The odds ratio of ever coffee consumption adjusted for age, sex, area, and amount of smoking was 1.25 (95% CI 0.95-1.64). Additional adjustment for years of education, intake of fruits and vegetables, urbanicity of longest residence until age 18, and having ever worked in high-risk occupations led, respectively, to the following ORs: 1.24 (0.94-1.63), 1.21 (0.92-1.60), 1.25 (0.95-1.64, 1.23 (0.93-1.64). Adjusting additionally for total fluid consumption and average lifetime THM levels in the household (available for a subset) did not affect the risk estimates. The OR adjusted for fluids was 1.18 (0.83-1.68) versus the unadjusted 1.18 (0.83-1.68) (n = 1,465). The OR adjusted by THM was 1.56 (1.09-2.21) versus the unadjusted 1.57 (1.11-2.24). By smoking status, ever coffee consumption was associated with an increased risk of bladder cancer among smokers (Table 3 ). The interaction between coffee consumption and smoking (never/ever) was 0.043. By gender, OR for ever coffee consumption was 1.32 (95% CI 0.97-1.79) among men and 1.06 (95% CI 0.58-1.93) among women (p-value for interaction 0.655). Among smokers, the OR for coffee consumption differed slightly in smokers by smoking patterns, but no evidence of effect modification was found. p-Values for interaction between ever coffee consumption and (i) duration of smoking (\30 vs. 30? years), (ii) amount of smoking (1-19 vs. 20 ? cigarettes/day), time since quitting among former smokers (\5 vs. 5? years), and (iv) tobacco type (blond, black, both) were 0.382, 0.773, 0.615, and 0.282, respectively. We stratified subjects according to the lifetime residential THM level above or below the population median (26 lg/l). OR of bladder cancer for ever coffee consumption was 1.85 (95% CI 1.09-3.14) among subjects below the median and 1.38 (0.86-2.21) among subjects above the median THM level. There was no evidence of interaction between coffee consumption and THM level (p-value 0.563).
We did not identify gene-coffee interactions for the evaluated SNPs in NAT2, CYP1A2, and CYP1A1. Although the interaction p-value for CYP2E1 (rs2070676) was statistically significant (0.03), it did not retain significance after adjusting for multiple comparisons (p-value 0.179). (Table 4) . We found no evidence of interactions between CYP1A1 haplotypes, coffee intake (\4 vs. C4 cups/day), and bladder cancer risk (p-value 0.094). For CYP2E1 haplotypes, p-value was 0.033 but it did not retain significance as well after applying the FDR procedure. Coffee consumption was highly correlated with smoking habits, and residual confounding cannot be ruled out in smokers. Among never smokers, although coffee consumption was moderate and the statistical power in heavy coffee drinkers was limited, we did observe a non-significant increased risk of bladder cancer in heavy coffee consumers (4 daily cups of coffee or more). In addition, a marginally significant interaction between coffee and smoking was found (0.045), suggesting that the effect of coffee could be modified by smoking status.
Coffee intake in the study population is very similar to the consumption described in a study conducted in Italy during 1997-2000, where average coffee consumption was 2.6 cups/day among cases and 2.1 cups/day among controls [15] . However, our consumption patters were modest compared to other studies and similar to consumption among non-smokers in previous studies. A pooled analysis of 10 case-control studies of bladder cancer conducted in six European countries including non-smokers reported an average coffee consumption of 2.1 cups/day in hospital controls and 2.9 cups/day in population controls [13] . Higher intakes were found in a case-control study of bladder cancer conducted in the Netherlands [5] , where average coffee consumption was 3.0 and 2.1 cups/day, respectively, in men and women classified as low coffee consumers and 6.5 and 5.1 cups/day, respectively, in men and women classified as heavy coffee consumers. In our study, 70% of study subjects consumed two cups of coffee per day or less, and average consumption among controls was 2.2 cups/day.
Although coffee is a complex mixture, the selection of genes in our analyses was focused on caffeine. This is a vast oversimplification, and SNPs that could be relevant for coffee metabolism may well have not been analyzed. In addition, we had a limited number of SNPs for CYP1A2, the most consistently associated with caffeine metabolism. The previous study evaluating gene-coffee interactions was not specifically focused on coffee-metabolizing enzymes, and results are only comparable and consistent for NAT2. This is the first study evaluating gene-coffee interactions for bladder cancer for most of the genes we evaluate and results remain preliminary.
In conclusion, coffee consumption was highly correlated with smoking habits, and the increased risk of bladder cancer among coffee drinkers could partly be explained by residual confounding among smokers. Among never smokers, an increased risk was only observed in the highest category of coffee drinking (4? cups/day).
